Listar por autor "Fernández Calvo, Ovidio"
Mostrando ítems 1-3 de 3
-
A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus
Vázquez Estévez, Sergio; Anido Herranz, Urbano; Lázaro Quintela, Martín; Fernández Calvo, Ovidio; Fernández-Núñez, Natalia; Dios Álvarez, N. de; Varela, V.; Campos Balea, B.; Agraso, S.; Areses, M. C.; Iglesias, L.; Blanco, Moisés; Maciá, S.; Antón-Aparicio, Luis M. (Springer, 2020-02-15)[Abstract] Background This article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methods This article especially performs an in-depth review of currently available ... -
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
Lázaro Quintela, Martín; León Mateos, Luis; Vázquez Estévez, Sergio; Fernández Calvo, Ovidio; Anido Herranz, Urbano; Afonso Afonso, Francisco Javier; Santomé, Lucía; Antón-Aparicio, Luis M. (Elsevier, 2015-03)[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ... -
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer
Anido Herranz, Urbano; Fernández Calvo, Ovidio; Afonso Afonso, Francisco Javier; Rodríguez Martínez de Llano, Sofía; Lázaro Quintela, Martín; León Mateos, Luis; Vázquez Estévez, Sergio; Antón-Aparicio, Luis M. (Taylor & Francis, 2015-01-02)[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to ...